Trial Profile

Efficacy and Safety of Intravenous YOLT-201 for Transthyretin Amyloidosis Cardiomyopathy

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 21 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs YOLT 201 (Primary)
Indications Transthyretin-related hereditary amyloidosis
Focus Adverse reactions

Most Recent Events

14 Feb 2025 Phase changed from phase 1 to early phase 1, hence protocol was amended.
14 Feb 2025 Planned End Date changed from 16 Oct 2025 to 10 Feb 2026.
14 Feb 2025 Planned primary completion date changed from 16 Oct 2024 to 3 Jul 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com